Perrigo Company plc (PRGO) - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on May 7, 2025. The filing announces the release of earnings results for the first quarter ended March 29, 2025. The company's ordinary shares and various notes are traded on the New York Stock Exchange.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures rather than reporting the results themselves.
The company utilizes non-GAAP measures to evaluate ongoing operating trends. These measures exclude items such as:
- Amortization expense related to acquired intangible assets.
- Unusual litigation costs.
- Restructuring charges and termination benefits.
- Impairment charges.
- Infant formula remediation costs.
- Losses on divestitures and investment securities.
- Foreign currency translation movements.
Material Changes and Adjustments
The filing outlines the specific adjustments made to derive non-GAAP results for the three months ended March 29, 2025, compared to the prior year period ended March 30, 2024. Notable adjustments for the current period include "Infant formula remediation" and "Loss on divestitures and investment securities," which were not explicitly listed as separate line items in the prior year's adjustment list (though "Acquisition and integration-related charges" were present in the prior year).
Guidance, Outlook, and Risks
Management states that non-GAAP measures are used for planning, forecasting, and determining compensation. The filing emphasizes that these supplemental measures should be considered in conjunction with, not as a substitute for, GAAP financial statements. No specific forward-looking guidance, risk factors, or contingency details are provided within this specific 8-K text; investors are directed to the attached press release (Exhibit 99.1) for detailed commentary.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for actual revenue, net income, and EPS figures.
- Verify the specific dollar amounts associated with "Infant formula remediation" and "Loss on divestitures."
- Compare GAAP versus non-GAAP reconciliations to assess the impact of excluded items on profitability.
- Check for any updates on the company's debt obligations (Notes due 2030, 2032, 2043, and 2044) in the full earnings release.